Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.67Last Year’s EPS
0.56Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: -8.20%
|Next Earnings Date:Apr 23, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with strong revenue and EPS growth exceeding expectations, particularly in the cardiology and electrophysiology segments. However, challenges such as significant tariff impacts, slower growth in certain segments, and foreign exchange headwinds were noted, adding some concerns to the otherwise strong performance.Company Guidance
During the Boston Scientific First Quarter 2025 Earnings Call, the company reported robust financial performance and provided updated guidance. The firm's operational sales grew by 22%, with organic sales increasing by 18%, both surpassing the high end of the guidance range of 14% to 16%. Adjusted EPS for the quarter was $0.75, a 34% growth that exceeded the guidance range of $0.66 to $0.68. The adjusted operating margin was reported at 28.9%. Looking forward, Boston Scientific raised its full-year organic growth guidance from 10% to 12% to a range of 12% to 14%, reflecting strong performance in its cardiology portfolio. The company also provided second-quarter organic growth guidance of 13% to 15% and adjusted EPS guidance of $0.71 to $0.73, with a full-year adjusted EPS range of $2.87 to $2.94, indicating growth of 14% to 17%. Despite a $200 million impact from tariffs, the company plans to offset this through increased sales and strategic cost reductions.Exceptional Revenue Growth
Total company operational sales grew 22% and organic sales grew 18%, both exceeding the high end of the guidance range of 14% to 16%.
Adjusted EPS Exceeds Guidance
First quarter adjusted EPS of $0.75 grew 34%, exceeding the high end of the guidance range of $0.66 to $0.68.
Cardiology Segment Performance
Cardiology delivered another fantastic quarter with sales growing 31%, including a 24% growth in WATCHMAN and 9% in interventional cardiology therapies.
Electrophysiology Leadership
Electrophysiology sales grew 145%, and the company is now the #2 player globally in EP.
Strong Regional Growth in the U.S.
The U.S. grew 31% with double-digit growth in 5 of 8 business units.
---
BSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | $103.54 | $104.97 | +1.38% |
| Oct 23, 2024 | $88.01 | $87.45 | -0.64% |
| Jul 24, 2024 | $78.59 | $77.76 | -1.06% |
| Apr 24, 2024 | $68.99 | $72.91 | +5.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Boston Scientific (BSX) report earnings?
Boston Scientific (BSX) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is Boston Scientific (BSX) earnings time?
Boston Scientific (BSX) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BSX EPS forecast?
BSX EPS forecast for the fiscal quarter 2025 (Q1) is 0.67.
---
